Seoud Muhieddine, Jaafar Iman, Ghanem Rayan, Soubhieh Christiane, Adra Abdallah, Nassar Anwar, Khalil Ali
American University of Beirut Medical Center (AUBMC), Department of Obstetrics and Gynecology, Beirut, Lebanon.
Obstet Gynecol Int. 2022 Oct 12;2022:7342061. doi: 10.1155/2022/7342061. eCollection 2022.
The study aims to report on the feasibility and associated adverse events of HPV-Vaccination (HPVV) in a private clinic setting in Lebanon and, when available, the results of subsequent cervical cancer screening.
Opportunistic HPV vaccination is offered at the Women's Health Center of the AUBMC. We retrospectively reviewed the patients' demographic data, the incidence of adverse events, and their cytological screening.
A cohort of healthy women ( = 1013) aged 26.2 years (12-54 years) were opportunistically vaccinated with one of two HPV vaccines; 845 (83.4%) received the quadrivalent vaccine (Q4V), and 151 (14.1%) received the bivalent vaccine (B2V). The majority (75.8%) received three doses while 16% received two doses. Out of these women, 26.3% (267) became sexually active postvaccination (NS2), whereas 17% (174) were sexually active prior to vaccination (SA) and the rest 57% (572) reported no sexual activity (NS1). Among the SA group, 26% (46/147) presented with abnormal cytology at time of vaccination. As for the NS2 women, 5% (14/267) had subsequently abnormal screening within 37 (12-103) months following vaccination.
In this observational study, we report the successful introduction of HPVV with negligible adverse events. The incidence of abnormal cervical cytology was low among our patients.
本研究旨在报告在黎巴嫩一家私人诊所环境中进行人乳头瘤病毒疫苗接种（HPVV）的可行性及相关不良事件，并在可获取数据时报告后续宫颈癌筛查的结果。
在AUBMC妇女健康中心提供机会性人乳头瘤病毒疫苗接种。我们回顾性地审查了患者的人口统计学数据、不良事件发生率及其细胞学筛查情况。
一组年龄为26.2岁（12 - 54岁）的健康女性（n = 1013）接受了两种人乳头瘤病毒疫苗之一的机会性接种；845人（83.4%）接种了四价疫苗（Q4V），151人（14.1%）接种了二价疫苗（B2V）。大多数（75.8%）接种了三剂，而16%接种了两剂。在这些女性中，26.3%（267人）在接种疫苗后开始有性行为（NS2），而17%（174人）在接种疫苗前就有性行为（SA），其余57%（572人）报告没有性行为（NS1）。在SA组中，26%（46/147）在接种疫苗时细胞学检查异常。至于NS2组的女性，5%（14/267）在接种疫苗后的37个月（12 - 103个月）内随后筛查结果异常。
在这项观察性研究中，我们报告了成功引入人乳头瘤病毒疫苗接种，不良事件可忽略不计。我们的患者中宫颈细胞学异常的发生率较低。
